Tine Kold Olesen

MSc, Exec. MBA

Role in PharmNovo: Business advisor.

Born: 1963.

Education: MSc in Pharmacy from Copenhagen University in 1992, DK; Exec. MBA from Imperial College, London, UK in 2012.

Work experience: Tine is currently based in US and has 25 years of experience in pharmaceutical industry. She has worked at Ferring Pharmaceuticals in US and in Denmark for the past 18 years where she directs integrated clinical development programs from early stage to life cycle management in uro-/oncology with responsibility for the design and development of novel strategies from early stage and through marketing authorization, followed by market access in R&D. Her key focus is within CMC and clinical development, directing regulatory actions, including NDA submissions and FDA advisory committee, interpretation of scientific data, building the value story and development of new businesses. Tine has prior experience in the therapeutic fields of Parkinson’s disease, epilepsy, diabetes, and migraine headaches within large pharma companies (Novo, GSK, and Orion).

Member of:

Business advisors

Latest news

View all

April 17, 2026

Watch PharmNovo at LSX in Lisbon

Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.

April 9, 2026

Capsules ready for Phase IIa Study

PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.

January 30, 2026

Welcome on Board

As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.

November 26, 2025

Endowed Chair awarded

We are delighted to share that Professor Amynah Pradhan has been awarded a prestigious Endowed Chair at Washington University, where she now serves as the Russell D. and Mary B. Shelden Professor of Anesthesiology.